SEATTLE, Nov. 13, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) has noted the fall in its share price over the last week of trading.  Omeros is not aware of any reason that justifies this decrease. As disclosed in Omeros' recent press releases and its Quarterly Report on Form 10-Q filed on November 9, 2012 with the US Securities and Exchange Commission, Omeros' business, including its clinical programs and its preclinical pipeline, remains on track and the Company is pleased with its progress.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

SOURCE Omeros Corporation

Jennifer Cook Williams, Cook Williams Communications, Inc., Investor and Media Relations, +1-360-668-3701, jennifer@cwcomm.org